Kronos Bio has announced the appointment of Deborah Knobelman as president and interim chief executive officer, effective from 3 December 2024. Dr Knobelman will also become principal executive and ...
The European Commission has approved mirvetuximab soravtansine for select patients with pretreated folate receptor–alpha (FRα)-positive, platinum-resistant ovarian cancer.